๐ In the midst of joy and festivities, let's remember why we do what we do and get motivated to keep going in 2024! Wishing you a fantastic conclusion to 2023! ๐
We are humbled to have been a finalist in the 'One to Watch' category at the @OBN_UK Awards in London! ๐ The recognition from the UK biotech network reaffirms the value of our mission. Congrats to all winners โ your accomplishments inspire us to push boundaries! ๐ #OBNAwards
Two extremely useful papers making med chem a little bit less hard, both from the @LevinChem Lab! Congrats! https://t.co/jmeqAtTXrZ https://t.co/caFYPpSfzI #CtoN#medchem#science#nature
๐๏ธ Tomorrow is #DagTegenKanker, a day of unity against this formidable foe. Let's stand together in support of patients and champion research for new therapies! Together, we can make a difference. ๐ช๐ฌ #CancerResearch#SupportPatients @komop_tgkanker https://t.co/ivNYbnYjCh
๐We have exciting news โ we are FINALISTS of the BioSeed One-to-Watch category for the @OBN 2023 #OBNAwards.
Join us at The Royal Lancaster in London on November 22nd.
Find out more at https://t.co/iS7pxpH2xB
#lifesciences#innovation#achievement#celebration
Amalus Therapeutics will be showcasing to the local community for the very first time today! Exciting and important moment! See you at the 4th @crighent industrial partnering event!
CRIG hosts its 4th industrial partnering event on 6 Oct! We bring together different actors in oncology & create opportunities for collaborations. Join our interactive program with industrial and academic speakers @ugent@uzgent@VIBLifeSciences via https://t.co/wp3On4Ton2
CRIG hosts its 4th industrial partnering event on 6 Oct! We bring together different actors in oncology & create opportunities for collaborations. Join our interactive program with industrial and academic speakers @ugent@uzgent@VIBLifeSciences via https://t.co/wp3On4Ton2
September was over before I realized it had started! What an exciting first month for me and Amalus, learning about being a founder, people management, and counting beans while doing science. And what a pleasure to do it with the other @BioCPH Institute Venture Lab 5 startups!
2023 #NobelPrize laureate in physiology or medicine Katalin Karikรณ (@kkariko) was born in 1955 in Szolnok, Hungary.
She is a professor at Szeged University and an adjunct professor at @Penn.
https://t.co/Dzq0SNJOUD
BREAKING NEWS
The 2023 #NobelPrize in Physiology or Medicine has been awarded to Katalin Karikรณ and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
We proudly support @komop_tgkanker and its current charity plant sale! Thanks to all volunteers for supporting people affected by cancer, their loved ones and the support and research community! #plantjesweekend#kotk#komoptegenkanker https://t.co/VCRcHvnxrm
29e Plantjesweekend Kom op tegen Kanker op vr 15, za 16 en zo 17 september 2023
... en ook de weergoden zetten hun beste beentje voor, met droog, vrij zonnig en aangenaam nazomerweer. ๐
https://t.co/x8kdClfNiR
@komop_tgkanker
When Dan Shechtman discovered a new type of crystal in 1982 he could not believe it. His quasicrystals were considered to be impossible and he faced much criticism before they were accepted by the scientific community.
Which discovery will receive this year's chemistry prize?
๐ฌ We have been selected for the BII Venture Lab! ๐This marks a significant milestone in our journey towards revolutionizing fibroblast-targeted treatments. We look forward to sharing the upcoming milestones and successes with all of you as we embark on this exciting chapter!
Ready, set, GO!๐ฅ
We are thrilled to announce our latest Venture Lab cohort consisting of seven start-ups, Amalus Therapeutics, Leopard Biosciences, Visibuilt, Rapidemic, BioHalo, Loma Therapeutics, and metaLead, as well as one corporate-sponsored venture from @Novozymes. Check them out below๐
Ready, set, GO!๐ฅ
We are thrilled to announce our latest Venture Lab cohort consisting of seven start-ups, Amalus Therapeutics, Leopard Biosciences, Visibuilt, Rapidemic, BioHalo, Loma Therapeutics, and metaLead, as well as one corporate-sponsored venture from @Novozymes. Check them out below๐
What we do (2/2)? Our technology modulates disease-associated fibroblasts with unprecedented selectivity, resulting in precise tissue remodeling and normalization. This generates multiple therapeutic benefits, ultimately improving patient survival and quality of life.